Eslicarbazepine acetate as adjunctive treatment in partial-onset epilepsy.
Saved in:
| Title: | Eslicarbazepine acetate as adjunctive treatment in partial-onset epilepsy. |
|---|---|
| Authors: | Lattanzi, S., Cagnetti, C., Foschi, N., Lorusso, A., Provinciali, L., Silvestrini, M. |
| Source: | Acta Neurologica Scandinavica. Jan2018, Vol. 137 Issue 1, p29-32. 4p. |
| Subjects: | Adjunctive behavior, Treatment of epilepsy, Adverse health care events, Anticonvulsants, Retrospective studies |
| Abstract: | Objective The aim of the study was to assess the clinical response to eslicarbazepine acetate ( ESL) as add-on therapy in adult patients with partial-onset epilepsy by means of the time-to-baseline seizure count method. Methods We retrospectively identified consecutive patients with partial-onset seizures, with or without secondary generalization, prescribed to ESL add-on therapy. The primary endpoint was the time-to-baseline monthly seizure count. Subgroup analysis was performed according to carbamazepine ( CBZ)/oxcarbazepine ( OXC) status ( prior vs never use). Secondary outcomes were the rate of treatment-related adverse events ( AEs) and the AEs affecting ≥5% of patients. Results One-hundred and eighteen patients were included. The median time-to-baseline monthly seizure count was 46 (35-101) days in the overall study cohort. The number of concomitant anti-epileptic drugs ( AEDs) was associated with the time-to-endpoint (adjusted hazard ratio [adj HR]=2.22, 95% CI 1.18-4.14, P=.013 for two AEDs vs one; adj HR=3.65, 95% CI 1.66-8.06, P=.001 for three or more AEDs vs one). Groupwise, the median times-to-baseline seizure count were 47 (35-97) and 43 (34-103) in patients with prior and never exposure to CBZ/ OXC, respectively ( P for log-rank test=.807). Adverse events occurred in 53.4% (63 of 118) of patients; the most frequently reported were dizziness (13.6%), somnolence (11.9%), nausea (6.8%), and fatigue (5.1%). Conclusions Add-on ESL improved seizure control and was overall well-tolerated in adult patients with partial-onset epilepsy. [ABSTRACT FROM AUTHOR] |
| Copyright of Acta Neurologica Scandinavica is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Objective The aim of the study was to assess the clinical response to eslicarbazepine acetate ( ESL) as add-on therapy in adult patients with partial-onset epilepsy by means of the time-to-baseline seizure count method. Methods We retrospectively identified consecutive patients with partial-onset seizures, with or without secondary generalization, prescribed to ESL add-on therapy. The primary endpoint was the time-to-baseline monthly seizure count. Subgroup analysis was performed according to carbamazepine ( CBZ)/oxcarbazepine ( OXC) status ( prior vs never use). Secondary outcomes were the rate of treatment-related adverse events ( AEs) and the AEs affecting ≥5% of patients. Results One-hundred and eighteen patients were included. The median time-to-baseline monthly seizure count was 46 (35-101) days in the overall study cohort. The number of concomitant anti-epileptic drugs ( AEDs) was associated with the time-to-endpoint (adjusted hazard ratio [adj HR]=2.22, 95% CI 1.18-4.14, P=.013 for two AEDs vs one; adj HR=3.65, 95% CI 1.66-8.06, P=.001 for three or more AEDs vs one). Groupwise, the median times-to-baseline seizure count were 47 (35-97) and 43 (34-103) in patients with prior and never exposure to CBZ/ OXC, respectively ( P for log-rank test=.807). Adverse events occurred in 53.4% (63 of 118) of patients; the most frequently reported were dizziness (13.6%), somnolence (11.9%), nausea (6.8%), and fatigue (5.1%). Conclusions Add-on ESL improved seizure control and was overall well-tolerated in adult patients with partial-onset epilepsy. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 00016314 |
| DOI: | 10.1111/ane.12803 |
